METH hydrochloride was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA) and APETx2 was from Tocris Bioscience (Bristol, UK). Both were dissolved in physiological saline (SAL) and delivered intraperitoneally at the doses of 0.5 mg/kg (METH) or 0.02 mg/kg (APETx2). The doses are based on previous studies demonstrating the addiction-like behavior-inducing effects of METH (Kim et al., 2019 (link), 2021 (link)) and the moderate ASIC3-inhibiting effect of APETx2 (Andreev et al., 2018 (link)). Treatments for molecular experiments were performed at zeitgeber (ZT) 4-5, where ZT 0 and 12 are lights on and off, respectively, based on previous studies (Abarca et al., 2002 (link); Hood et al., 2010 (link)).